Pirfenidone
- Generic Name
- Pirfenidone
- Brand Names
- Esbriet, Pirfenidone axunio (previously Pirfenidone AET), Pirfenidone Viatris
- Drug Type
- Small Molecule
- Chemical Formula
- C12H11NO
- CAS Number
- 53179-13-8
- Unique Ingredient Identifier
- D7NLD2JX7U
- Background
Pirfenidone is a synthetic pyridone drug. It is an antifibrotic agent with anti-inflammatory and antioxidant properties that is used to treat idiopathic pulmonary fibrosis (IPF), which is a chronic, progressive form of interstitial pneumonia. While its mechanism of action is not yet fully understood, pirfenidone is proposed to primarily regulate tumor necro...
- Indication
Pirfenidone is indicated for the treatment of idiopathic pulmonary fibrosis (IPF). In Canada and Europe, it is approved in adults only.
- Associated Conditions
- Idiopathic Pulmonary Fibrosis (IPF), Mild Idiopathic Pulmonary Fibrosis, Moderate Idiopathic Pulmonary Fibrosis
- Associated Therapies
- -
Pirfenidone to Treat Hypertrophic Cardiomyopathy
- Conditions
- First Posted Date
- 2001-02-12
- Last Posted Date
- 2008-03-04
- Target Recruit Count
- 50
- Registration Number
- NCT00011076
- Locations
- 🇺🇸
National Heart, Lung and Blood Institute (NHLBI), Bethesda, Maryland, United States
Pirfenidone to Treat Kidney Disease (Focal Segmental Glomerulosclerosis)
- Conditions
- First Posted Date
- 2000-01-19
- Last Posted Date
- 2014-05-26
- Target Recruit Count
- 21
- Registration Number
- NCT00001959
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Oral Pirfenidone for the Pulmonary Fibrosis of Hermansky-Pudlak Syndrome
- Conditions
- Interventions
- First Posted Date
- 1999-11-04
- Last Posted Date
- 2017-10-16
- Lead Sponsor
- William Gahl, M.D.
- Target Recruit Count
- 35
- Registration Number
- NCT00001596
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.